Current dividend yield | 8.77 % |
Dividendenrendite 5 Jahre | 7.81 % |
Dividend Yield 10Y | 7.41 % |
Payout 3Y | 2.36 % |
Year | Dividend | Ex-day & Payday |
Frequency | |
---|---|---|---|---|
Fiscal Year | Dividend per Share | Ex-Day | Payday | Payment frequency |
2024 |
AUD0.05
AUD0.05
|
Sep 05 2024
Sep 05 2024
Sep 20 2024
Sep 05 24
Sep 20 24 |
Sep 20 2024 |
-
-
|
2023 |
AUD0.05
AUD0.05
|
Sep 05 2023
Sep 05 2023
Sep 20 2023
Sep 05 23
Sep 20 23 |
Sep 20 2023 |
-
-
|
2022 |
AUD0.04
AUD0.04
|
Sep 06 2022
Sep 06 2022
Sep 21 2022
Sep 06 22
Sep 21 22 |
Sep 21 2022 |
-
-
|
2021 |
AUD0.025
AUD0.03
|
Sep 02 2021
Sep 02 2021
Sep 17 2021
Sep 02 21
Sep 17 21 |
Sep 17 2021 |
-
-
|
2020 |
AUD0.025
AUD0.03
|
Sep 03 2020
Sep 03 2020
Sep 18 2020
Sep 03 20
Sep 18 20 |
Sep 18 2020 |
-
-
|
2019 |
AUD0.025
AUD0.03
|
Sep 04 2019
Sep 04 2019
Sep 19 2019
Sep 04 19
Sep 19 19 |
Sep 19 2019 |
-
-
|
2018 |
AUD0.02
AUD0.02
|
Sep 21 2018
Sep 21 2018
Oct 08 2018
Sep 21 18
Oct 08 18 |
Oct 08 2018 |
-
-
|
Clinuvel Pharmaceutical most recently paid a dividend of AUD0.05. Clinuvel Pharmaceutical paid a Dividend of AUD0.05 Per Share in the financial year 2024. With a stock price of AUD14.72 at Sep 06 2024, the current dividend yield is 0.34% (calculation: AUD0.05 / AUD14.72 = 0.34%). No special dividend was paid.
The average Clinuvel Pharmaceutical dividend yield over the last 5 years is 0.17% and the average over the last 10 years is 0.15%.
The payout ratio of Clinuvel Pharmaceutical in relation to the last financial year is 6.94%. The payout ratio smoothed over 3 years is 7.95%. The calculation is based on the sum of all dividend payments divided by the cumulative earnings per share(EPS).
Metric | Clinuvel Pharmaceutical |
---|---|
Current dividend yield | 0.34% |
Dividend Yield 5Y | 0.17% |
Dividend Yield 10Y | 0.15% |
Payout 1Y | 6.94% |
Payout 3Y | 7.95% |
Clinuvel Pharmaceutical has been paying a dividend for 7 years and has not lowered the dividend for 7 years (dividend continuity). As a result, the dividend was not increased recently.
The Dividend Growth in relation to the previous financial year amounts to 0.00%. The average Clinuvel Pharmaceutical Dividend Growth over the last 5 years is 14.87%.
Metric | Clinuvel Pharmaceutical |
---|---|
Increased | 0 Years |
Continuity | 7 Years |
Paid | 7 Years |
Growth 1Y | 0.00% |
Growth 5Y | 14.87% |
Clinuvel Pharmaceutical has been paying a dividend for 7 years and has not lowered the dividend for 7 years (dividend continuity). As a result, the dividend was not increased recently.
The Dividend Growth in relation to the previous financial year amounts to 0.00%. The average Clinuvel Pharmaceutical Dividend Growth over the last 5 years is 14.87%.
On the stock exchange, the Clinuvel Pharmaceutical stock (ISIN: AU000000CUV3) is not traded as a top scorer in September 2024 according to the dividend strategy.
The stock price of Clinuvel Pharmaceutical -7.70% has fallen since the beginning of the year 2024. However, the return generated in the past says nothing about the future return. You can find the Clinuvel Pharmaceutical stock price in real time at the top of the page.
Clinuvel Pharmaceutical (symbol: CUV) is valued at a Price / Earnings Ratio (P/E ratio) of 20.69 and a price/sales ratio (P/S ratio) of 8.36 valued. Based on analyst estimates, the Clinuvel Pharmaceutical stock forecast 2024 of the current financial year corresponds to a valuation of 19.41 according to P/E ratio and 7.50 according to P/S.
Metric | Clinuvel Pharmaceutical |
---|---|
Dividend Score | ??/15 |
Performance 2024 |
7.70%
|
P/E TTM | 20.69 |
P/S TTM | 8.36 |
P/E forward | 19.41 |
P/S forward | 7.50 |
Clinuvel Pharmaceutical (symbol: CUV) is valued at a Price / Earnings Ratio (P/E ratio) of 20.69 and a price/sales ratio (P/S ratio) of 8.36 valued. Based on analyst estimates, the Clinuvel Pharmaceutical stock forecast 2024 of the current financial year corresponds to a valuation of 19.41 according to P/E ratio and 7.50 according to P/S.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.